Candriam SCA’s AdaptHealth AHCO Stock Holding History

Candriam SCA’s Portfolio AHCO Stock Details AHCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,931	Closed	-$787K	–	877
2022 Q4	$787K	Sell	40,931 -13,876	-25%	-$293K	0.01%	749
2022 Q3	$1.03M	Buy	+54,807	New	+$1.13M	0.01%	698

Other funds holding AHCO

OCA

OEP Capital Advisors New York $194M AUM 9.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SkyKnight Capital San Francisco, California $107M AUM 9.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA's AHCO Position: Q1 2023 in Review

Candriam SCA sold out of AdaptHealth (AHCO) in Q1 2023, closing a stake of 40,931 shares — an estimated $787K sold.

Candriam SCA first reported a position in AHCO in Q3 2022 and held it in 2 quarters. The position peaked at $1.03M in Q3 2022. 172 funds tracked by Wall St. Rank hold AHCO as of Q1 2023.

Candriam SCA reported no remaining AdaptHealth position as of Q1 2023 after selling out during the quarter.
Candriam SCA sold 40,931 AdaptHealth shares in Q1 2023, an estimated $787K.
Candriam SCA first reported a position in AdaptHealth in Q3 2022 and held it in 2 quarters.
Candriam SCA's AdaptHealth position peaked at $1.03M in Q3 2022.
172 funds tracked by Wall St. Rank held AdaptHealth as of Q1 2023.

Based on Candriam SCA's 13F filing for Q1 2023, filed 12 May 2023.